US HIFU manufactures the Sonablate 500 (Sonablate) medical device to treat prostate cancer with HIFU energy, which is approved in more than 30 countries outside the US and is currently under investigation in the US within an FDA approved IDE.
In this role, Klein will oversee theUS HIFU’s other operations, including market development for the Sonablate outside of the US and the Sonatherm 600, US HIFU’s first 510(k)-cleared.
He previously served as president of the radiation oncology division of Roper Industries.
At Xoft, he served as president and CEO from 2005 until the sale of Xoft to iCAD in December 2010.
Klein led the development, approval and commercialization of Xoft’s non-radioactive x-ray technology for radiation therapy for various cancers.
Klein served as chairman, president and CEO of R2 Technology from 2000 to 2004 , where he oversaw the clinical trial and PMA process for R2’s computer-aided detection technology that received approval for both breast and lung cancer detection.
From 1997 to 2000, he also served as general manager of Varian Medical Systems’ oncology group where he managed businesses ranging from $25m to $250m.
At Sanarus Medical,a company focused on the treatment of fibroadenomas, Klein served on the board of directors.
